Tuesday, 27 October 2026European Markets

AKER SOLUTIONS Stock Rises By 16% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of AKER SOLUTIONS (Oslo Børs All-share Index_GI: AKSO.OL) jumped by a staggering 16.25% in 5 sessions from 38.02 kr to 44.20 kr at 19:25 EST on Friday, after two successive sessions in a row of gains. Oslo Børs All-share Index_GI is rising 0.37% to 1,418.24 kr, after three sequential sessions in a row of losses.

About AKER SOLUTIONS

Aker Solutions ASA provides solutions, products, systems, and services to the oil and gas industry worldwide. It offers field planning, feasibility, and concept studies; specialist engineering, project management, and procurement services; floater designs, offshore wind, as well as engages in design, delivery, and construction of deepwater risers, oil, and gas production, and receiving and processing facilities. In addition, the company provides offshore fish farming, carbon capture, utilization and storage, hydrogen, and offshore wind solutions. Further, the company designs and constructs jackets for construction services and offers electrification services. Additionally, the company provides subsea production, compression, pump, power distribution, and processing systems, and subsea lifecycle services. Furthermore, the company offers maintenance, modifications, decommissioning, asset integrity management, hook-up, and completion solutions. Aker Solutions ASA was founded in 1841 and is headquartered in Fornebu, Norway.

Earnings Per Share

As for profitability, AKER SOLUTIONS has a trailing twelve months EPS of -3.13 kr.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AKER SOLUTIONS's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for AKER SOLUTIONS is 1029456 which is 23.54% below its average volume of 1104420.

More news about AKER SOLUTIONS (AKSO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com